Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid and biotin before radiolabeling

Clinical Cancer Research

Volumn 11, Issue 19 II, 2005, Pages

  Wang, Zhongmin ^a,d   Mårtensson, Linda ^a   Nilsson, Rune ^c   Bendahl, Pär Ola ^a   Lindgren, Lars ^c   Ohlsson, Tomas ^b   Sjögren, Hans Olov ^b   Strand, Sven Erik ^b   Tennvall, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Mitra Medical AB   (Sweden)

^d SHANXI TUMOR HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (13' THIOUREABENZYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID)TRIOXADIAMINE 1 (13'' BIOTIN ASPARTIC ACID HYDROXYL)TRIOXADIAMINE 5 ISOTHIOCYANATOAMINOISOPHTHALATE; BIOTIN; INDIUM 111; MITRATAG; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BR96; REAGENT; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN BINDING; CANCER IMMUNOTHERAPY; CHELATION; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG UPTAKE; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; AVIDIN; BIOTIN; CHELATING AGENTS; DOXORUBICIN; HETEROCYCLIC COMPOUNDS, 1-RING; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; QUALITY CONTROL; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RATS; TIME FACTORS;

EID: 26444545539     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1004-0001     Document Type: Conference Paper

References (30)

1. Leyland-Jones B, Gelmon K, Ayoub J-P, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965-71.
2. Paganelli G, Chinol M. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:773-6.
3. Strand SE, Zanzonico P, Johnson TK. Pharmacokinetic modelling. Med Phys 1993;20:515-27.
4. Norrgren K, Strand SE, Nilsson R, Lindgren L, Lilliehorn P. A general extracorporeal immunoadsorpation method to increase tumor-normal tissue ratio in radioimmunoimaging and radioimmunotherapy. J Nucl Med 1993;34:448-54.
5. Chen J, Strand SE, Tennvall J, Lindgren L, Hindorf C, Sjögren HO. Extracorporeal immunoadsorption compared to avidin chase: enhancement of tumor-to-normal tissue ratio for biotinylated rhenium-188-chimeric BR96. J Nucl Med 1997;38:1934-9.
6. 125I-labeled BR-96-biotin monoclonal antibody in syngeneic rat tumor model. J Nucl Med 1997;38:895-901.
7. Tennvall J, Garkavij M, Chen J, Sjögren HO, Strand SE. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96. Cancer 1997;80:2411-8.
8. 125I- and (111) In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption. Clin Cancer Res 1999;5:3059-64s.
9. Wang ZM, Garkavij M, Tennvall J, Ohlsson T, Strand SE, Sjögren HO. Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of In-111-HMFG1-biotin. Cancer 2002;94:1287-92s.
10. Rossi NR, Ullen A, Sandstrom P, et al. Dosimetry of fractionated experimental radioimmunotargeting with idiotypic and anti-idiotypic anticytokeratin antibodies. Cancer 1997;80:2681-8s.
11. Wilbur DS, Chyan MK, Hamlin DK, et al. Trifunctional conjugation reagents, reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies. Bioconjug Chem 2002;13:1079-92.
12. Juweid M, Sharkey RM, Alavi A, et al. Regression of advanced refractory ovarian cancer treated with I-131-labeled anti-CEA monoclonal antibody. J Nucl Med 1997;38:257-60.
13. Sharkey RM, Goldenberg DM, Murthy S, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993;71:2082-96.
14. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
15. Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000;18:3230-9.
16. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2637-48.
17. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000;26:269-86.
18. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 2000;18:2282-92.
19. 111In-MN14 using an avidin-affinity column in rats. Cancer Biother Radiopharm 2003;18:365-75.
20. Green NM. A spectrophotometric assay for avidin and biotin based on binding dyes by avidin. Biochem J 1965;94:23-5c.
21. 131I pair-labeled, biotinylated chimeric BR96 in colon carcinoma isografted rats. Tumor Targeting 1996;2:204-14.
22. Ghetie V, Ward ES, Witetta ES. Pharmacokinetics of antibodies and immunotoxins in mice and humans. In: Figg WD, Mcleod HL, editors. Handbook of anticancer pharmacokinetics and pharmacodynamics. Totowa (New Jersey): Humana Press Inc.; 2004. p. 475-98.
23. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001.
24. Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 2000;22:295-301.
25. Scheidhauer K, Wolf I, Baumgartl HJ, et al. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002; 29:1276-82.
26. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73.
27. Garnett MC. Targeted drug conjugates: principle and progress. Adv Drug Deliv Rev 2001;53:171-216.
28. Eccles SA. Models for evaluation of targeted therapies of metastatic disease. In: Teicher BA, editor. Tumor models in cancer research. Totowa (New Jersey): Humana Press Inc.; 2002, pp. 293-319.
29. Sjôgren HO, Isaksson M, Willner D, Hellstrom I, Hellstrom KE, Trail PA. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 1997;57:4530-6.
30. 90Y-anti-CD20-biotin MAb in patients with refractory lymphoma. ASCO 40th Annual Meeting, New Orleans (Los Angeles): 2004 Abstract 6576.